Evommune’s phase 2b flops, ending challenge to Novartis in hives
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis…
Roche’s COPD drug flunks phase 3, denting hopes of 2025 approval
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken…
Roche sees Alnylam RNAi drug flunk trial, still plans phase 3
Roche’s hypertension med zilebesiran may have failed to hit the primary endpoint of the last in a trio of…
Novartis narrows anticoagulant’s focus after losing to Eliquis
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials…